7TM Pharma Announces the Selection of a New Pre-Clinical Development Candidate

7TM Pharma A/S has selected a new pre-clinical development candidate, TM38837, for the treatment of obesity and related metabolic diseases. TM38837 is derived from 7TM Pharma's discovery program targeting the development of Cannabinoid type 1 receptor antagonists, CB1 antagonists, acting specifically in the periphery of the body. TM38837 has shown a substantial and robust weight reduction effect in various chronic animal models for obesity. Importantly, it has further been shown to have a very favorable side effect profile in various animal models compared to other known CB1 antagonists. CB1 antagonists have been demonstrated in a number of clinical trials to reduce body weight and improve obesity associated risk factors, for example Type 2 diabetes.

"We are very excited about our peripherally acting CB1 program and the selection of our first pre-clinical candidate from this program." says Mette Kirstine Agger, CEO of 7TM Pharma. "Previous CB1 antagonists have shown clear effects in terms of weight reduction and improvement of associated risk factors. Maintaining this effect with TM38837, while simultaneously improving the safety profile is an important step forwards towards safe and effective medicines in this field and significantly strengthens our pipeline focusing on metabolic disorders."

For further information please contact:

Mette Kirstine Agger,

CEO

Tel: +45 3925 7777

Email: agger@7tm.com

Or visit: www.7tm.com